Clinical research in South Africa needs to be reorganized and revitalized, says ASSAf report

10 May 2010

There is a need to revitalize and reorganize clinical research in South Africa, according to a new, peer-reviewed report by the Academy of Science of South Africa (ASSAf) has released a peer-reviewed, titled Revitalizing Clinical Research in South Africa: A Study on Clinical Research and Related Training in South Africa.

Clinical research activity and capacity in SA has declined dramatically, prompting the ASSAf, following discussions with the Pharmaceutical Industry Association of South Africa (PIASA), to undertake this study in order to make recommendations on the overall revitalization of clinical research in the country within the framework of essential national health research.

'Clinical research in a developing country like South Africa contributes to health care at all levels by identifying the causes of problems, facilitating diagnosis, improving the efficiency and effectiveness of care, and promoting good policy-making,' says the report. 'It also supports the training of competent health professionals of all kinds, and contributes to global knowledge about locally, as well as generally, prevalent diseases in terms of prevention and treatment,' it adds.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight





More Features in Pharmaceutical